Results 71 to 80 of about 191,459 (192)

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah, Bridges, Ian, Cheng, Lung-I, Dent, Ricardo, Deshpande, Sohan, Forbes, Carol A., Gandra, Shravanthi R., Kleijnen, Jos, Ross, Janine, Sattar, Naveed, Stroes, Erik S.G., Toth, Peter P., Worth, Gavin M., Worthy, Gillian   +13 more
core   +1 more source

Nocebo effects by providing informed consent in shared decision making? Not necessarily: a randomized pilot-trial using an open-label placebo approach

BMC Medical Ethics, 2020
Background Thorough information of the patient is an integral part of the process of shared decision making. We aimed to investigate if detailed information about medication may induce nocebo (or placebo) effects.
Fabian Holzhüter, Johannes Hamann
doaj   +1 more source

Non-Deceptive Placebos Can Promote Acts of Kindness: A Randomized Controlled Trial

Behavioral Sciences, 2023
Placebos have often been used to reduce emotional distress but rarely to increase positive feelings. The present study investigated whether a placebo can promote acts of kindness (AoKs) that are associated with emotional well-being.
Anne Schienle, Isabella Unger
doaj   +1 more source

The Role of Rituals in Open-Label Placebo Effects

, 2023
Placebos have been shown to generate beneficial effects on mental health and well-being even when they are administered openly, without deception. However, research on open-label placebos (OLPs) is limited and there is still some uncertainty regarding how OLP effects can be created consistently.
openaire   +2 more sources

Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis [PDF]

, 2018
Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107 ...
Achuthan, Akagawa, Aletaha, Aletaha, Antoniu, Avci, Berghen, Borg, Borie, Brown, Buch, Burmester, Burmester, Calisto, Cella, Chen, Cook, Cornish, Cottin, Crotti, Dawson, Felson, Fleetwood, Fries, Greven, Guo, Hamilton, Jaguin, Kelly, Khan, Lazaro, Listing, Minter, Prevoo, Shaw, Shibata, Singh, Tsuchiya, Van der Heijde, Van Gestel, Van Onna, Ware, Weinblatt, Yoshida, Zhan   +44 more
core   +1 more source

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease [PDF]

, 2014
Background Crohn’s disease (CD) is a chronic relapsing inflammatory condition. Many patients fail to achieve remission with medical management and require surgical interventions.
Angelberger, Angelberger, Ardizzone, Armuzzi, Armuzzi, Armuzzi, Benchimol, Bernell, Colonna, D'Haens, D'Haens, Dilger, Doherty, Ferrante, Gordon, Guyatt, Hafraoui, Hanauer, Hanauer, Herfarth, Herfarth, Higgins, Higgins, Korelitz, Manosa, Mañosa, Nos, Pitkin, Prefontaine, Regueiro, Reinisch, Reinisch, Reinisch, Reinisch, Rolfe, Rutgeerts, Savarino, Savarino, Savarino, Schünemann, Steinhart, Williams   +41 more
core   +1 more source

Safety Profile of Opicapone in the Management of Parkinson’s Disease

Journal of Parkinson’s Disease, 2019
Background: Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson’s disease (PD) and motor fluctuations.
Andrew Lees, Joaquim J. Ferreira, José-Francisco Rocha, Olivier Rascol, Werner Poewe, Helena Gama, Patrício Soares-da-Silva   +6 more
doaj   +1 more source

Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control

PAIN Reports, 2020
Introduction:. Opioid consumption for those in comprehensive inpatient rehabilitation units is high because of the complexity of their injuries. Notably, pain in rehabilitation leads to worsened clinical outcomes because of maladaptive behaviors and poor
Leon Morales-Quezada, Ines Mesia-Toledo, Anayali Estudillo-Guerra, Kevin C. O'Connor, Jeffrey C. Schneider, Douglas J. Sohn, David M. Crandell, Ted Kaptchuk, Ross Zafonte   +8 more
doaj   +1 more source

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

BMC Gastroenterology, 2023
Background Short-term efficacy and safety of brazikumab (MEDI2070), a human monoclonal antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in patients with moderate-to-severe active Crohn’s disease (CD).
Silvio Danese, Andrew Beaton, Elizabeth A. Duncan, Anne-Kristina Mercier, Jessica Neisen, Henrik Seth, Sofia Zetterstrand, Bruce E. Sands   +7 more
doaj   +1 more source

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]

, 2017
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie, Hansen, Oluf K.H., Hartoft-Nielsen, Marie-Louise, Jabbour, Serge, Pieber, Thomas R., Rosenstock, Julio   +5 more
core   +1 more source